
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics is supported by a mature, profitable base business, with 9M26 gross margin at 64%, adjusted EBITDA meaningfully positive, and FY26 guidance raised on both revenue and margin. Its OEM channel represented 56% of 9M26 revenue and the commercial channel 44%, while no debt and $38.4M in cash provide balance-sheet flexibility to fund execution and buybacks. Upside is further driven by de-risked pipeline optionality: Cingal has three positive Ph3 trials, FDA said only a bioequivalence study remains before filing, and Hyalofast’s clarity lets investors focus on margin execution and the core HA franchise.
Bears say
Anika Therapeutics is facing a fundamental regulatory overhang as Hyalofast remains under FDA review, with the Phase III study missing its pre-specified co-primary endpoints and the company receiving a deficiency letter in 1Q26 tied to CMC and clinical data. The delayed approval timeline, now outside management’s control, also forced the company to exclude the previously implied $3 million of US Hyalofast revenue from its 2027 outlook, signaling limited near-term contribution from this program. Despite established overseas use in more than 35 countries and over 40,000 implantations, the uncertainty around US commercialization compounds an already concentrated revenue base that depends heavily on OEM and US-market products marketed exclusively by Johnson & Johnson MedTech.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Anika Therapeutics (ANIK) Forecast
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares